TB-500 — 10mg

TB-500 is a synthetic heptapeptide derived from the actin-binding domain of the naturally occurring 43-amino acid protein Thymosin Beta-4. While full-length Tβ4 has broad intracellular roles, TB-500 isolates the biologically active region responsible for the protein's tissue-remodeling effects — making it an effective and more tractable research compound. Its primary mechanism involves sequestering actin monomers and finely modulating actin filament assembly dynamics, which in turn drives the cytoskeletal changes necessary for cell migration into damaged tissue.

Beyond actin regulation, TB-500 activates the ILK/Akt survival pathway, promoting cell survival in hypoxic and inflammatory environments. This pathway is particularly well-characterized in cardiac models, where TB-500 administration has been shown to induce angiogenesis in ischemic myocardium and improve cardiomyocyte survival following infarct. In dermal and corneal wound models, the peptide consistently accelerates re-epithelialization and reduces scar formation — effects that have positioned it as a subject of active ophthalmological research.

The musculoskeletal flexibility and anti-fibrotic properties documented in animal models make TB-500 a frequent subject of sports medicine research. Its complementary mechanisms to BPC-157 — particularly its emphasis on cell survival and systemic mobility versus BPC-157's focus on local receptor sensitization — have made the two peptides a common pairing in combined healing protocols.